Abstract: The invention is in the field of molecular biology, and relates to recombinant engineering and protein expression. More in particular, the invention relates to nucleic acids for recombinant expression of proteins comprising sequences derived from Lactococcus and useful as promoters. The invention further relates to vectors comprising the nucleic acids and host cells transformed therewith. The invention also covers the use of host cells comprising the nucleic acids or vectors for expressing heterologous or homologous proteins; and also for delivery, especially therapeutic delivery, of the said proteins to subjects.

Abstract: The present invention provides an agent for inhibition of alcoholic hepatopathy comprising cells of a strain belonging to Lactobacillus brevis, or treated product thereof as an active ingredient. The agent for inhibition of alcoholic hepatopathy of the present invention is safe for living body and can be used as a component in foods and beverages.

Abstract: The invention relates to spray-dried Lactobacillus strains and/or Lactobacillus cells (lactic acid bacteria) and to the uses thereof, in particular for pharmaceutical and/or dietary compositions for the treatment and prophylaxis of Helicobacter pylori infections in humans and animals.

Abstract: The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.

Abstract: Provided is a bacteriocin that is capable of being easily mass-produced, has high antimicrobial activity even at low concentration, has a wide antimicrobial spectrum, and is less likely to produce resistant microorganisms. The bacteriocin has the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING, or has the same amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 2 in SEQUENCE LISTING except that one or several amino acids are deleted, substituted, inserted and/or added, wherein the amino acid sequence provides antimicrobial activity and the isoelectric point is not less than 12.

Abstract: Cycloserine resistant mutants of lactic acid bacteria characterized by having improved resistance towards ethanol. The cycloserine resistant mutants of lactic acid bacteria can e.g. be used for malolactic fermentations of wine (i.e. including sparkling wine such as Cava/champagne) having high alcohol levels.

Abstract: TRFs useful for identifying strains of interest are provided. A method of identifying one or more strain that can be used as a direct-fed microbial is also provided. One or more strain identified by the method is additionally provided. A method is also provided for administering to an animal an effective amount of the one or more strain. Additionally provided is an isolated strain chosen from at least one of Lactobacillus acidophilus strain P1B c6 (NRRL B-50103), Lactobacillus salivarius strain o246e 33w (NRRL B-50102), Pediococcus acidilactici strain o246e 42 (NRRL B-50171), and Pediococcus acidilactici strain P1J e3 (NRRL B-50101). An isolated strain having all of the identifying characteristics of one of the strains listed above is also provided. One or more strain can be administered as a direct-fed microbial to an animal. Methods of preparing a direct-fed microbial are also provided.

Abstract: This invention relates to a fruit-based food product such as beverages or fruit purees, comprising a concentration of live and stable probiotics, which is preferably greater than 108 CFU/ml, a high fruit content, which is preferably greater than 50%, and a low organic acid content, and wherein the production of off-tastes is reduced or diminished in relation to the initial fruit matrix, as well as method for preparing a food product such as this.

Abstract: A method for liver protection of a mammal is provided and includes administering an effective amount of isolated Lactobacillus plantarum CMU995 thereto. Providing a new use of Lactobacillus plantarum CMU995, which is deposited at the Food Industry Research and Development Institute (FIRDI) in Taiwan under accession number BCRC 910472 and in the German Collection of Microorganisms and Cell Cultures (DSMZ) under accession number DSM 23780.

Abstract: New strains of Lactobacillus paracasei which can be used as probiotics in dairy products and which are characterized in surviving the gastrointestinal passage and giving a palatable cheese product when used as an adjunct in cheese manufacturing. The invention especially refers to the new strains Lactobacillus paracasei 8700:2, DSM 13434, and Lactobacillus paracasei 02A, DSM 13432. The invention also refers to dairy food products, such as cheese, containing said strains.

Abstract: The present invention relates to methods for the screening, identification and/or application of microorganisms of use in imparting beneficial properties to plants.

Abstract: A selection of strains of lactic bacteria and bifidobacteria of human intestinal origin capable of metabolizing oxalates is described. Moreover, a food composition or supplement product or pharmaceutical composition containing said bacterial strains is also described.

Abstract: Disclosed are novel Lactobacillus plantarum strains as well as a composition containing the novel Lactobacillus plantarum strains or a culture thereof.

Abstract: The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an animal. An alternative treatment method comprises administering a therapeutically effective amount of a lactic acid producing bacterium such as Lactobacillus acidophilus in combination with a lactate utilizing bacterium such as Propionibacterium freudenreichii.

Abstract: The present invention refers to a strain of Lactobacillus curvatusbacteria deposited in the Deutsche Sammlung von Mikroorganismen and Zellkulturen GmBH (DSMZ) under the accession number DSM 18775, as well as to compositions, cultures and food products comprising thereof. The strain of the invention is useful for preserving food products, especially under refrigerated conditions.

Abstract: The invention relates to the new, genetically non-modified bacterial strain Lactobacillus plantarum S, which has been deposited in the IAFB Collection of Industrial Microorganisms Institute of Agricultural and Food Biotechnology in Warsaw under the number KKP 2021 p or variant thereof. The invention relates to use of the strain Lactobacillus plantarum S KKP 2021 p or variant thereof or composition which may comprise thereof for ensiling of roughages, with the intention to decontaminate the feeds, contaminated with ochratoxin A, molds and pathogenic bacteria. The feeds contaminated with molds, ochratoxin A and pathogenic microorganisms, after the process of lactic fermentation with the participation of bacteria of the new strain Lactobacillus plantarum S, may be employed in nutrition of breeding animals as being completely safe products.

Abstract: The present invention is related to the field of bioprotection, in particular to an antimicrobial composition comprising a Lactobacillus rhamnosus strain and/or a Lactobacillus paracasei strain. Furthermore, the present invention concerns uses for such an antimicrobial composition, food, feed and pharmaceutical products comprising such an antimicrobial composition, a method of manufacturing such food, feed and pharmaceutical products and a method for reducing the content of unwanted microorganisms of such food, feed and pharmaceutical products.

Abstract: Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents are extracts of a bacterium, or a bacterium and are selected for their adhesion to skin cells and anti-adhesion to pathogens of the cutaneous system. The invention also relates to compositions containing such agents.

Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.

Abstract: A composition comprising probiotic bacteria for use in the pharmacological treatment of gastric hyperacidity is described. The composition is capable of restoring the barrier effect of the stomach which is lost during pharmacological treatment of gastric hyperacidity and minimizes the secondary effects due to said pharmacological treatment.

Abstract: Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: This invention relates to polybacterial probiotic preparation, which includes new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No 8722 and Lactobacillus helveticus A1, NBIMCC No 8721 and has the following set of properties: antioxidant, hypocholesterolemic effect, anti-inflammatory immunomodulating effect, ability to release bioactive peptides that inhibit angiotensin-converting enzyme (ACE), which is responsible for the high blood pressure. The object of invention is also the described probiotic strains of lactic acid bacteria and the developed bacterial products with useful properties. The incorporated probiotic strain Lactobacillus gasseri 7/12 NBIMCC No. 8720, has a number of properties: strong adhesion to the epithelial layer of the colon, the ability for reduction of cholesterol and anti-inflammatory effects by reducing the levels of proinflammatory cytokine interleukin-8.

Abstract: This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.

Abstract: The present invention relates to a composition having antioxidant activity. Furthermore, the present invention relates to probiotic bacteria having antioxidant activity and the use thereof.

Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.

Abstract: The invention describes a microorganism of the order of lactic acid bacteria or an analogue, fragment, derivative, mutant or combination thereof, wherein the microorganism, or analogue, fragment, derivative, mutant or combination thereof can coaggregate with Streptococcus pyogenes.

Abstract: A specific method is provided of improving immunomodulatory properties of Lactobacillus strains using growth media with a specific primary carbon source, including a method of increasing the anti-inflammatory effect of non-pathogenic anti-inflammatory bacterial strains, by the use of specific growth conditions.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: The use of probiotic bacteria in the manufacture of a composition for administration to a woman in at least the third trimester of pregnancy for prevention of gestational diabetes, normalizing plasma glucose concentration and/or increasing insulin sensitivity.

Abstract: The invention relates to a novel strain of Lactobacillus delbrueckii having blood-cholesterol-lowering properties, and to the use thereof for the manufacture of blood-cholesterol-lowering fermented products, in particular of milk products.

Abstract: Bacteria that are not natural butanol producers were found to have increased tolerance to butanol when the membrane content of unsaturated trans fatty acids was increased. Feeding cells with unsaturated trans fatty acids increased their concentration in the membrane, which may also be accomplished by expressing a fatty acid cistrans isomerase.

Abstract: The present invention relates to new microorganism strains L. plantarum MCC1 DSM 23881 and L. gasseri MCC2 DSM 23882 and their use as antioxidant proteolytic ingredients for the production of food products and dietary supplements. Food products and dietary supplements containing L. plantarum MCC1 and L. gasseri MCC2 are hypoallergenic, reduce milk allergy and lower urinary tract irritation symptoms accompanying benign prostatic hyperplasia and oxidative stress and inflammation associated with these.

Abstract: Disclosed is an anti-fatty liver agent comprising a cell and/or a culture obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri as an active ingredient. Also disclosed is a pharmaceutical agent having an anti-fatty liver activity or an anti-fatty liver beverage/food comprising a cell and/or a culture obtained by culturing a lactic acid bacterium belonging to Lactobacillus gasseri as an active ingredient.

Abstract: The present invention relates to methods and compositions for Lactobacillus Replacement Therapy (LRT). Methods for improved stability and recovery of dried bacterial preparations are also provided.

Abstract: The invention relates to probiotic micro-organisms isolated from faeces of children exclusively fed with breast milk. Said microorganisms are used in the food or pharmaceutical industry, especially for use in infant formula milk, due to their probiotic properties which have beneficial effects on the health of those ingesting them. Said microorganisms consist of Lactobacillus rhamnosus HERO 22A (CNCM I-4036), Lactobacillus paracasei HERO 7 (CNCM I-4034) and Bifidobacterium breve HERO 15B (CNCM I-4035).

Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.

Abstract: The present invention relates to novel strains of Lactobacillus helveticus that can produce high amounts of hypotensive peptides, in particular IPP, VPP and LPP. It also relates to a fermented milk product containing a mixture of tripeptides IPP-VPP-LPP and a strain of L. helveticus. The invention further relates to the specific peptide mixture consisting of tripeptides IPP, VPP and LPP and the use of the fermented product or mixture of peptides in food products, food supplement or pharmaceutical compositions for reducing or preventing hypertension.

Abstract: An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species Lactobacillus reuteri and is capable of producing lipases having the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5 or amino acid sequences having deletion, substitution or addition of one or more amino acids in the amino acid sequences respectively depicted in SEQ ID NO: 1, 3 or 5. The anti-obesity agent enables a patient to take a normal meal yet preventing the absorption of a fat into the body which is the primary cause of obesity.

Abstract: The present invention relates to a composition suitable for preparing a dairy product comprising at least one starter culture and a Lactobacillus rhamnosus strain capable of imparting onto the dairy product and enhanced creamy flavor without affecting the rheology negatively, the fonnentation time or the post-acidification of the dairy product. The present invention further relates to processes for preparing a dairy product, such as a low-fat yoghurt or cheese, which has a high content of diacetyl. A Lactobacillus rhamnosus strain useful for preparing such dairy product is also part of the present invention.

Abstract: A subject of the invention is a composition containing strains Lactobacillus fermentum 57A, Lactobacillus plantarum 57B and Lactobacillus gasseri 57C of special characteristics such as a feature of strong diversified affinity for the digestive tract and vaginal epithelia enabling the colonization of the vagina and anus after the crossover through intestines as well as the feature of co-aggregation enabling for synergetic activity. The subject of the invention is also the application of the composition for restoration of the natural bacterial flora of the vagina and anus.

Abstract: The present invention relates to microbial inocula and in particular to standardised inocula for producing reference cultures of microorganisms. The invention has been developed primarily for use as a solid, disc-shaped, inoculum and will be described hereinafter with reference to this application. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: A method of enhancing the antimicrobial properties of a bacterial strain, comprising cultivation of the bacterial strain in a medium comprising water, at least one component chosen from bee pollen, pollen, and bee bread, and optionally honey and/or nectar is described. The bacterial strain has the ability to be viable for at least 8 days in a 65% by weight sugar solution, preferably at least 8 days in a 70% by weight sugar solution.

Abstract: Described are microorganisms which are able to suppress the production of malodorous compounds by axillary bacteria. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.

Abstract: A process for concentrating microorganism-containing suspensions comprising (a) centrifuging a microorganism-containing suspension to provide a first microorganism-containing concentrate and a supernatant liquid; (b) filtering said first microorganism-containing concentrate, to provide a permeate and a second microorganism-containing concentrate.

Abstract: The invention provides a probiotic composition to alleviate Salmonella infection in farm animals. The composition may comprise at least one of Lactobacillus murinus, Lactobacillus pentosus, Lactobacillus salivarius sub-species salivarius, and Pediococcus pentosaceus. The composition maybe formulated as an animal feedstuff, or as a pharmaceutical composition.

Abstract: The invention provides certain plasmid cured strains of lactic acid bacteria modified for their capability of better acid-tolerance, a method of modifying such strains, and products containing such strains.

Abstract: Liquid microbial starter culture that retains its initial metabolic activity during storage for extended periods of time. Such liquid starter cultures are useful in the manufacturing of food and feed products. Starter cultures of the invention include culture of lactic acid bacteria, e.g. Lactococcus species.

Abstract: The present application includes a process and a microorganism of the genus Lactobacillus that converts glycerol to 1,3-propanediol. The conversion is accomplished by a proprietary microorganism that is easily cultured in glycerol rich waste products of ethanol production, such as thin stillage.

Abstract: The invention relates to a microorganism growth substrate which comprises a sterile nutrient composition derived from the biomass of a culture of bacteria including methanotrophic bacteria and further containing at least one sterile nutrient. A preferred biomass material is that derived from a microbial culture comprising Methylococcus capsulates (Bath) (strain NCIMB 41526), Ralstonia sp. DB3 (strain NCIMB 41527) and Brevibacillus agri DB5 (strain NCIMB 41525), optionally in combination with Aneurinibacillus sp. DB4 (strain NCIMB 41528).